Sign inJoin waitlistJoin the waitlist

James Ingle

Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · ·

History

Mayo Clinic College of Medicine and Science
Present

National Institutes of Health
Osler Medical Service The Johns Hopkins Hospital
Microbiology University of Iowa School of Medicine
Johns Hopkins Univ Sch of Med

Research

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
New England Journal of Medicine · 2005 · 4,152 citations
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
Systematic review or meta-analysis · The Lancet · 2011 · 2,398 citations
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
New England Journal of Medicine · 2003 · 1,382 citations

Matthew Goetz
101 papers
Richard Weinshilboum
62 papers
PG
Paul Goss
58 papers
EP
Edith Perez
49 papers
EC
Edward Creagan
40 papers
SM
Silvana Martino
39 papers
Nancy Davidson
31 papers
SF
Stephen Frytak
30 papers
Judy Boughey
24 papers · 4 as a resident
LK
Larry Kvols
23 papers
Hyman Muss
21 papers
JE
John Edmonson
20 papers

Grants

Mayo Clinic Breast Cancer SPORE
National Cancer Institute · P50
Contact PI · $26.7M · Mayo Clinic Rochester
2005–2022
Mayo Clinic Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $890.4K · Mayo Clinic Rochester
1988–2003
Development of Breast Cancer Research Program
National Cancer Institute · R21
Contact PI · $939.3K · Mayo Clinic Rochester
1994–1999
Development of Breast Cancer Research Program
National Cancer Institute · P20
Contact PI · $232.7K · Mayo Clinic Rochester
1994–1998

Clinical trials

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Principal investigator · Completed · Phase 2
Mayo Clinic
2007–2019
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer
Principal investigator · Completed
Mayo Clinic
2005–2010
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
Principal investigator · Completed · Phase 2
SRI International
2004–2008
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer
Principal investigator · Completed · Phase 2
Mayo Clinic
2003–2006